Celldex Therapeutics, Inc. — Director's Dealing 2023

Jun 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2023-06-15

Reporting Person: Marucci Anthony S (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-15	Incentive Stock Option (right to buy)	$36.87	A	250000	Acquired	2033-06-15	Common Stock (250000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.